Involvement of Signaling Cascades in Granulocytopoiesis Regulation under Conditions of Cytostatic Treatment. 2020

V V Zhdanov, and L A Miroshnichenko, and G N Zyuz'kov, and E V Udut, and T Yu Polyakova, and E V Simanina, and E Yu Sherstoboev, and L A Stavrova, and V I Agafonov, and M Yu Minakova, and A V Chaikovskii, and A M Dygai
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

Suppression of the production of granulocytic CSF under the effect of 5-fluorouracyl is related to disorders in the NF-κB-, cAMP-dependent signaling pathways and MAPK cascade. These secondary messengers are involved in the regulation of functional activity of nonadherent myelokaryocytes starting from day 10 of the experiment (initial period of the hemopoietic granulocytic stem regeneration after antimetabolite challenge). Granulocytic CSF does not play essential role in the formation of colony-stimulating activity of cells of the adherent and nonadherent fractions of the bone marrow. Only cAMP-dependent pathway is involved in the regulation of the realization of the granulocytic precursor growth potential in response to the challenge.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006052 Gold Sodium Thiomalate A variable mixture of the mono- and disodium salts of gold thiomalic acid used mainly for its anti-inflammatory action in the treatment of rheumatoid arthritis. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis. Aurothiomalate,Gold Thiomalate,Sodium Gold Thiomalate,Aurolate,Gold Disodium Thiomalate, Monohydrate,Gold Thiomalic Acid,Mercaptobutanedioic Acid Monogold(1+) Sodium Salt,Miocrin,Miocrisin,Monogold (1+) Disodium Thiomalate,Myochrysine,Myocrisin,Myocrysine,Sodium Aurothiomalate,Sodium Thiomalatoaurate,Tauredon,Aurothiomalate, Sodium,Gold Thiomalate, Sodium,Sodium Thiomalate, Gold,Thiomalate, Gold,Thiomalatoaurate, Sodium

Related Publications

V V Zhdanov, and L A Miroshnichenko, and G N Zyuz'kov, and E V Udut, and T Yu Polyakova, and E V Simanina, and E Yu Sherstoboev, and L A Stavrova, and V I Agafonov, and M Yu Minakova, and A V Chaikovskii, and A M Dygai
January 2006, Eksperimental'naia i klinicheskaia farmakologiia,
V V Zhdanov, and L A Miroshnichenko, and G N Zyuz'kov, and E V Udut, and T Yu Polyakova, and E V Simanina, and E Yu Sherstoboev, and L A Stavrova, and V I Agafonov, and M Yu Minakova, and A V Chaikovskii, and A M Dygai
September 2007, Bulletin of experimental biology and medicine,
V V Zhdanov, and L A Miroshnichenko, and G N Zyuz'kov, and E V Udut, and T Yu Polyakova, and E V Simanina, and E Yu Sherstoboev, and L A Stavrova, and V I Agafonov, and M Yu Minakova, and A V Chaikovskii, and A M Dygai
April 2008, Bulletin of experimental biology and medicine,
V V Zhdanov, and L A Miroshnichenko, and G N Zyuz'kov, and E V Udut, and T Yu Polyakova, and E V Simanina, and E Yu Sherstoboev, and L A Stavrova, and V I Agafonov, and M Yu Minakova, and A V Chaikovskii, and A M Dygai
May 2009, Bulletin of experimental biology and medicine,
V V Zhdanov, and L A Miroshnichenko, and G N Zyuz'kov, and E V Udut, and T Yu Polyakova, and E V Simanina, and E Yu Sherstoboev, and L A Stavrova, and V I Agafonov, and M Yu Minakova, and A V Chaikovskii, and A M Dygai
May 2007, Bulletin of experimental biology and medicine,
V V Zhdanov, and L A Miroshnichenko, and G N Zyuz'kov, and E V Udut, and T Yu Polyakova, and E V Simanina, and E Yu Sherstoboev, and L A Stavrova, and V I Agafonov, and M Yu Minakova, and A V Chaikovskii, and A M Dygai
May 2000, Bulletin of experimental biology and medicine,
V V Zhdanov, and L A Miroshnichenko, and G N Zyuz'kov, and E V Udut, and T Yu Polyakova, and E V Simanina, and E Yu Sherstoboev, and L A Stavrova, and V I Agafonov, and M Yu Minakova, and A V Chaikovskii, and A M Dygai
January 2014, Advances in experimental medicine and biology,
V V Zhdanov, and L A Miroshnichenko, and G N Zyuz'kov, and E V Udut, and T Yu Polyakova, and E V Simanina, and E Yu Sherstoboev, and L A Stavrova, and V I Agafonov, and M Yu Minakova, and A V Chaikovskii, and A M Dygai
March 2010, Eksperimental'naia i klinicheskaia farmakologiia,
V V Zhdanov, and L A Miroshnichenko, and G N Zyuz'kov, and E V Udut, and T Yu Polyakova, and E V Simanina, and E Yu Sherstoboev, and L A Stavrova, and V I Agafonov, and M Yu Minakova, and A V Chaikovskii, and A M Dygai
November 2001, Biochemical and biophysical research communications,
V V Zhdanov, and L A Miroshnichenko, and G N Zyuz'kov, and E V Udut, and T Yu Polyakova, and E V Simanina, and E Yu Sherstoboev, and L A Stavrova, and V I Agafonov, and M Yu Minakova, and A V Chaikovskii, and A M Dygai
January 1988, Postepy higieny i medycyny doswiadczalnej,
Copied contents to your clipboard!